{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T10:00:37Z","timestamp":1777456837734,"version":"3.51.4"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s00393-026-01800-w","type":"journal-article","created":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T14:02:29Z","timestamp":1775656949000},"page":"307-316","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Kardiovaskul\u00e4re Risiken bei entz\u00fcndlich-rheumatischen Erkrankungen","Cardiovascular risk in inflammatory rheumatic diseases"],"prefix":"10.1007","volume":"85","author":[{"given":"Stefan","family":"Kleinert","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,8]]},"reference":[{"key":"1800_CR1","doi-asserted-by":"publisher","first-page":"3583","DOI":"10.1002\/art.22979","volume":"56","author":"A Gonzalez","year":"2007","unstructured":"Gonzalez\u00a0A, Maradit Kremers\u00a0H, Crowson\u00a0CS et\u00a0al (2007) The widening mortality gap between rheumatoid arthritis patients and the general population. Arthritis Rheum 56:3583\u20133587","journal-title":"Arthritis Rheum"},{"key":"1800_CR2","unstructured":"Listing J, Kekow J, Manger B et\u00a0al. (2013) Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNF\u03b1 inhibitors and rituximab. Annals of the Rheumatic Diseases"},{"key":"1800_CR3","doi-asserted-by":"publisher","first-page":"523","DOI":"10.7326\/M15-0919","volume":"164","author":"IM Markusse","year":"2016","unstructured":"Markusse\u00a0IM, Akdemir\u00a0G, Dirven\u00a0L et\u00a0al (2016) Long-Term Outcomes of Patients With Recent-Onset Rheumatoid Arthritis After 10 Years of Tight Controlled Treatment: A Randomized Trial. Ann Intern Med 164:523\u2013531","journal-title":"Ann Intern Med"},{"key":"1800_CR4","doi-asserted-by":"crossref","unstructured":"Joerns EK, Lopez-Ruiz A, Lennon RJ et\u00a0al. (2025) Differences in Cause-Specific Mortality in Patients with Rheumatoid Arthritis by Sex and Seropositivity. J\u00a0Rheumatol","DOI":"10.3899\/jrheum.2025-0361"},{"key":"1800_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2024.152382","volume":"65","author":"HK Aaramaa","year":"2024","unstructured":"Aaramaa\u00a0HK, Mars\u00a0N, Helminen\u00a0M et\u00a0al (2024) Risk of cardiovascular comorbidities before and after the onset of rheumatic diseases. Semin Arthritis Rheum 65:152382","journal-title":"Semin Arthritis Rheum"},{"key":"1800_CR6","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1002\/acr.24820","volume":"75","author":"H Chaudhary","year":"2023","unstructured":"Chaudhary\u00a0H, Bohra\u00a0N, Syed\u00a0K et\u00a0al (2023) All-Cause and Cause-Specific Mortality in Psoriatic Arthritis and Ankylosing Spondylitis: A Systematic Review and Meta-Analysis. Arthritis Care Res (Hoboken) 75:1052\u20131065","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"1800_CR7","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1136\/ard-2022-222259","volume":"82","author":"C Charles-Schoeman","year":"2023","unstructured":"Charles-Schoeman\u00a0C, Buch\u00a0MH, Dougados\u00a0M et\u00a0al (2023) Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance. Ann Rheum Dis 82:119\u2013129","journal-title":"Ann Rheum Dis"},{"key":"1800_CR8","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/art.41095","volume":"72","author":"JT Giles","year":"2020","unstructured":"Giles\u00a0JT, Sattar\u00a0N, Gabriel\u00a0S et\u00a0al (2020) Cardiovascular Safety of Tocilizumab Versus Etanercept in Rheumatoid Arthritis: A Randomized Controlled Trial. Arthritis rheumatology 72:31\u201340","journal-title":"Arthritis rheumatology"},{"key":"1800_CR9","doi-asserted-by":"crossref","unstructured":"Jani M, Curtis JR, Hyrich KL (2025) Navigating real-world data sources in rheumatology: opportunities, pitfalls, and practical guidance. Ann Rheum Dis","DOI":"10.1016\/j.ard.2025.11.018"},{"key":"1800_CR10","doi-asserted-by":"publisher","first-page":"3738","DOI":"10.1093\/rheumatology\/keaa850","volume":"60","author":"C Roubille","year":"2021","unstructured":"Roubille\u00a0C, Coffy\u00a0A, Rincheval\u00a0N et\u00a0al (2021) Ten-year analysis of the risk of severe outcomes related to low-dose glucocorticoids in early rheumatoid arthritis. Rheumatology (Oxford) 60:3738\u20133746","journal-title":"Rheumatology (Oxford)"},{"key":"1800_CR11","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41584-021-00593-3","volume":"17","author":"F Atzeni","year":"2021","unstructured":"Atzeni\u00a0F, Rodr\u00edguez-Carrio\u00a0J, Popa\u00a0CD et\u00a0al (2021) Cardiovascular effects of approved drugs for rheumatoid arthritis. Nat Rev Rheumatol 17:270\u2013290","journal-title":"Nat Rev Rheumatol"},{"key":"1800_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/ar2383","volume":"10","author":"A Naranjo","year":"2008","unstructured":"Naranjo\u00a0A, Sokka\u00a0T, Descalzo\u00a0MA et\u00a0al (2008) Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthritis Res Ther 10:R30","journal-title":"Arthritis Res Ther"},{"key":"1800_CR13","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000024579","volume":"100","author":"KJ Sun","year":"2021","unstructured":"Sun\u00a0KJ, Liu\u00a0LL, Hu\u00a0JH et\u00a0al (2021) Methotrexate can prevent cardiovascular events in patients with rheumatoid arthritis: An updated meta-analysis. Medicine (Baltimore) 100:e24579","journal-title":"Medicine (Baltimore)"},{"key":"1800_CR14","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1002\/acr.20371","volume":"63","author":"C Barnabe","year":"2011","unstructured":"Barnabe\u00a0C, Martin\u00a0BJ, Ghali\u00a0WA (2011) Systematic review and meta-analysis: anti-tumor necrosis factor alpha therapy and cardiovascular events in rheumatoid arthritis. Arthritis Care Res (Hoboken) 63:522\u2013529","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"1800_CR15","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","volume":"377","author":"PM Ridker","year":"2017","unstructured":"Ridker\u00a0PM, Everett\u00a0BM, Thuren\u00a0T et\u00a0al (2017) Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med 377:1119\u20131131","journal-title":"N Engl J Med"},{"key":"1800_CR16","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1002\/acr.23875","volume":"72","author":"S Singh","year":"2020","unstructured":"Singh\u00a0S, Fumery\u00a0M, Singh\u00a0AG et\u00a0al (2020) Comparative Risk of Cardiovascular Events With Biologic and Synthetic Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. Arthritis Care Res (Hoboken) 72:561\u2013576","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"1800_CR17","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1136\/annrheumdis-2015-207870","volume":"75","author":"J Zhang","year":"2016","unstructured":"Zhang\u00a0J, Xie\u00a0F, Yun\u00a0H et\u00a0al (2016) Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis. Ann Rheum Dis 75:1813\u20131818","journal-title":"Ann Rheum Dis"},{"key":"1800_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1004591","volume":"22","author":"TL Lin","year":"2025","unstructured":"Lin\u00a0TL, Fan\u00a0YH, Fan\u00a0KS et\u00a0al (2025) Cardiovascular disease risk in patients with psoriasis receiving biologics targeting TNF-alpha, IL-12\/23, IL-17, and IL-23: A population-based retrospective cohort study. PLoS Med 22:e1004591","journal-title":"PLoS Med"},{"key":"1800_CR19","doi-asserted-by":"crossref","unstructured":"Raby M, Balusson F, Oger E et\u00a0al. (2025) Interleukin-17 Inhibitors and Early Major Adverse Cardiovascular Events. JAMA Dermatol","DOI":"10.1001\/jamadermatol.2025.2972"},{"key":"1800_CR20","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jaad.2025.03.016","volume":"93","author":"B J","year":"2025","unstructured":"J\u00a0B, H\u00a0S, A\u00a0A et\u00a0al (2025) Long-term cardiovascular safety of ustekinumab in psoriasis and psoriatic arthritis: Results from an observational postauthorization safety study based on Swedish national registers. J\u00a0Am Acad Dermatol 93:104\u2013114","journal-title":"J Am Acad Dermatol"},{"key":"1800_CR21","unstructured":"European Medicines Agency (2022) EMA confirms measures to minimise risk of serious side effects with Janus kinase inhibitors for chronic inflammatory disorders."},{"key":"1800_CR22","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s40257-023-00783-7","volume":"24","author":"PJ Mease","year":"2023","unstructured":"Mease\u00a0PJ, Hatemi\u00a0G, Paris\u00a0M et\u00a0al (2023) Apremilast Long-Term Safety Up to 5 Years from 15 Pooled Randomized, Placebo-Controlled Studies of Psoriasis, Psoriatic Arthritis, and Behcet\u2019s Syndrome. Am J Clin Dermatol 24:809\u2013820","journal-title":"Am J Clin Dermatol"},{"key":"1800_CR23","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1136\/annrheumdis-2014-206624","volume":"74","author":"C Roubille","year":"2015","unstructured":"Roubille\u00a0C, Richer\u00a0V, Starnino\u00a0T et\u00a0al (2015) The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a\u00a0systematic review and meta-analysis. Annals of the Rheumatic Diseases 74:480\u2013489","journal-title":"Annals of the Rheumatic Diseases"},{"key":"1800_CR24","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1056\/NEJMoa1611593","volume":"375","author":"SE Nissen","year":"2016","unstructured":"Nissen\u00a0SE, Yeomans\u00a0ND, Solomon\u00a0DH et\u00a0al (2016) Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. N Engl J Med 375:2519\u20132529","journal-title":"N Engl J Med"},{"key":"1800_CR25","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-025-05975-4","volume":"45","author":"\u0410 Issakulova","year":"2025","unstructured":"Issakulova \u0410, Yessirkepov\u00a0M, Zimba\u00a0O et\u00a0al (2025) Cardiovascular risk in axial spondyloarthritis: the interplay of inflammation, traditional risk factors, and management strategies. Rheumatol Int 45:214","journal-title":"Rheumatol Int"},{"key":"1800_CR26","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/rheumatology\/kead684","volume":"64","author":"JW Kim","year":"2025","unstructured":"Kim\u00a0JW, Yoon\u00a0JS, Park\u00a0S et\u00a0al (2025) Risk of cardiovascular disease associated with long-term use of non-steroidal anti-inflammatory drugs in ankylosing spondylitis. Rheumatology 64:261\u2013267","journal-title":"Rheumatology"},{"key":"1800_CR27","doi-asserted-by":"crossref","unstructured":"Ocon AJ, Reed G, Pappas DA et\u00a0al (2021) Short-term dose and duration-dependent glucocorticoid risk for cardiovascular events in glucocorticoid-naive patients with rheumatoid arthritis. Ann Rheum Dis 80:1522\u20131529","DOI":"10.1136\/annrheumdis-2021-220577"},{"key":"1800_CR28","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s00393-018-0481-y","volume":"77","author":"C Fiehn","year":"2018","unstructured":"Fiehn\u00a0C, Holle\u00a0J, Iking-Konert\u00a0C et\u00a0al (2018) S2e-Leitlinie: Therapie der rheumatoiden Arthritis mit krankheitsmodifizierenden Medikamenten. Zeitschrift f\u00fcr Rheumatologie 77:35\u201353","journal-title":"Zeitschrift f\u00fcr Rheumatologie"},{"key":"1800_CR29","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/ard-2022-223356","volume":"82","author":"JS Smolen","year":"2023","unstructured":"Smolen\u00a0JS, Landew\u00e9\u00a0RBM, Bergstra\u00a0SA et\u00a0al (2023) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis 82:3\u201318","journal-title":"Ann Rheum Dis"},{"key":"1800_CR30","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1016\/S0140-6736(02)08213-2","volume":"359","author":"HK Choi","year":"2002","unstructured":"Choi\u00a0HK, Hernan\u00a0MA, Seeger\u00a0JD et\u00a0al (2002) Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 359:1173\u20131177","journal-title":"Lancet"},{"key":"1800_CR31","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/3424136","volume":"2018","author":"A Floris","year":"2018","unstructured":"Floris\u00a0A, Piga\u00a0M, Mangoni\u00a0AA et\u00a0al (2018) Protective Effects of Hydroxychloroquine against Accelerated Atherosclerosis in Systemic Lupus Erythematosus. Mediators Inflamm 2018:3424136","journal-title":"Mediators Inflamm"},{"key":"1800_CR32","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.3899\/jrheum.170926","volume":"45","author":"Y Jin","year":"2018","unstructured":"Jin\u00a0Y, Kang\u00a0EH, Brill\u00a0G et\u00a0al (2018) Cardiovascular (CV) Risk after Initiation of Abatacept versus TNF Inhibitors in Rheumatoid Arthritis Patients with and without Baseline CV Disease. J\u00a0Rheumatol 45:1240\u20131248","journal-title":"J Rheumatol"},{"key":"1800_CR33","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","volume":"383","author":"SM Nidorf","year":"2020","unstructured":"Nidorf\u00a0SM, Fiolet\u00a0ATL, Mosterd\u00a0A et\u00a0al (2020) Colchicine in Patients with Chronic Coronary Disease. N Engl J Med 383:1838\u20131847","journal-title":"N Engl J Med"},{"key":"1800_CR34","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.1161\/CIR.0000000000001168","volume":"148","author":"SS Virani","year":"2023","unstructured":"Virani\u00a0SS, Newby\u00a0LK, Arnold\u00a0SV et\u00a0al (2023) 2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation 148:e9\u2013e119","journal-title":"Circulation"},{"key":"1800_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1203372","volume":"14","author":"R Queiro","year":"2023","unstructured":"Queiro\u00a0R, Aurrecoechea\u00a0E, Alonso Castro\u00a0S et\u00a0al (2023) Interleukin-17-targeted treatment in patients with spondyloarthritis and associated cardiometabolic risk profile. Front Immunol 14:1203372","journal-title":"Front Immunol"},{"key":"1800_CR36","unstructured":"Krause A, Krueger K (2024) Januskinase-Inhibitoren (JAKi) \u2013 wie ist mit den Verordnungseinschr\u00e4nkungen umzugehen? - Aktualisierte Empfehlungen der Deutschen Gesellschaft f\u00fcr Rheumatologie und Klinische Immunologie. In:"},{"key":"1800_CR37","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1002\/art.43188","volume":"77","author":"R Aymon","year":"2025","unstructured":"Aymon\u00a0R, Mongin\u00a0D, Guemara\u00a0R et\u00a0al (2025) Incidence of Major Adverse Cardiovascular Events in Patients With Rheumatoid Arthritis Treated With JAK Inhibitors Compared With Biologic Disease-Modifying Antirheumatic Drugs: Data From an International Collaboration of Registries. Arthritis & rheumatology 77:1194\u20131204","journal-title":"Arthritis & rheumatology"},{"key":"1800_CR38","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003489","volume":"9","author":"Y Meissner","year":"2023","unstructured":"Meissner\u00a0Y, Schafer\u00a0M, Albrecht\u00a0K et\u00a0al (2023) Risk of major adverse cardiovascular events in patients with rheumatoid arthritis treated with conventional synthetic, biologic and targeted synthetic disease-modifying antirheumatic drugs: observational data from the German RABBIT register. RMD Open 9:e003489","journal-title":"RMD Open"},{"key":"1800_CR39","doi-asserted-by":"crossref","unstructured":"Giles JT, Charles-Schoeman C, Buch MH et\u00a0al. (2025) Use of statins and its association with major adverse cardiovascular events with tofacitinib vs TNF inhibitors in patients with rheumatoid arthritis with and without atherosclerotic cardiovascular disease. Ann Rheum Dis","DOI":"10.1016\/j.ard.2025.08.028"},{"key":"1800_CR40","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1136\/annrheumdis-2016-209775","volume":"76","author":"R Agca","year":"2017","unstructured":"Agca\u00a0R, Heslinga\u00a0SC, Rollefstad\u00a0S et\u00a0al (2017) EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015\/2016 update. Ann Rheum Dis 76:17\u201328","journal-title":"Ann Rheum Dis"},{"key":"1800_CR41","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1093\/rheumatology\/keaa683","volume":"60","author":"R Persson","year":"2021","unstructured":"Persson\u00a0R, Hagberg\u00a0KW, Qian\u00a0Y et\u00a0al (2021) The risks of major cardiac events among patients with psoriatic arthritis treated with apremilast, biologics, DMARDs or corticosteroids. Rheumatology (Oxford) 60:1926\u20131931","journal-title":"Rheumatology (Oxford)"},{"key":"1800_CR42","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1136\/annrheumdis-2021-221733","volume":"81","author":"GC Drosos","year":"2022","unstructured":"Drosos\u00a0GC, Vedder\u00a0D, Houben\u00a0E et\u00a0al (2022) EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome. Ann Rheum Dis 81:768\u2013779","journal-title":"Ann Rheum Dis"},{"key":"1800_CR43","unstructured":"Kassen\u00e4rztliche Bundesvereinigung (2025) Risiken fr\u00fchzeitig erkennen - Informationen f\u00fcr unsere Patienten. https:\/\/www.kbv.de\/documents\/infothek\/publikationen\/patienteninfo\/praevention\/vorsorgeplaner-frueherkennung-flyer.pdf"},{"key":"1800_CR44","doi-asserted-by":"publisher","first-page":"4227","DOI":"10.1093\/rheumatology\/keaf168","volume":"64","author":"J Llorca","year":"2025","unstructured":"Llorca\u00a0J, Castaneda\u00a0S, Ferraz-Amaro\u00a0I et\u00a0al (2025) Performance of four cardiovascular risk scales in chronic inflammatory rheumatic disease patients: 10-year follow-up data. Rheumatology (Oxford) 64:4227\u20134235","journal-title":"Rheumatology (Oxford)"},{"key":"1800_CR45","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/1529-0131(200001)43:1<14::AID-ANR3>3.0.CO;2-7","volume":"43","author":"D Krause","year":"2000","unstructured":"Krause\u00a0D, Schleusser\u00a0B, Herborn\u00a0G et\u00a0al (2000) Response to methotrexate treatment is associated with reduced mortality in patients with severe rheumatoid arthritis. Arthritis Rheum 43:14\u201321","journal-title":"Arthritis Rheum"},{"key":"1800_CR46","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1136\/annrheumdis-2013-204021","volume":"74","author":"J Listing","year":"2015","unstructured":"Listing\u00a0J, Kekow\u00a0J, Manger\u00a0B et\u00a0al (2015) Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFalpha inhibitors and rituximab. Ann Rheum Dis 74:415\u2013421","journal-title":"Ann Rheum Dis"},{"key":"1800_CR47","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","volume":"42","author":"FLJ Visseren","year":"2021","unstructured":"Visseren\u00a0FLJ, Mach\u00a0F, Smulders\u00a0YM et\u00a0al (2021) 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 42:3227\u20133337","journal-title":"Eur Heart J"},{"key":"1800_CR48","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1136\/annrheumdis-2014-eular.1142","volume":"73","author":"K Krueger","year":"2014","unstructured":"Krueger\u00a0K, Kleinert\u00a0S, Hecker\u00a0R et\u00a0al (2014) Implementation of the EULAR Recommendations for Cardiovascular Risk Management in Germany: Results of a Cross-Sectional Epidemiologic Study [abstr]. Ann Rheum Dis 73:172\u2013173","journal-title":"Ann Rheum Dis"},{"key":"1800_CR49","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1136\/annrheumdis-2018-eular.1268","volume":"77","author":"K Krueger","year":"2018","unstructured":"Krueger\u00a0K, Eder\u00a0R, Mueller\u00a0C et\u00a0al (2018) Assessing the risk of ra patients for comorbid conditions through a structured nurse-led interview \u2013 the eriko study (abstr). Annals of the Rheumatic Diseases 77:119","journal-title":"Annals of the Rheumatic Diseases"},{"key":"1800_CR50","doi-asserted-by":"publisher","first-page":"3518","DOI":"10.1093\/eurheartj\/ehaf384","volume":"46","author":"B Heidecker","year":"2025","unstructured":"Heidecker\u00a0B, Libby\u00a0P, Vassiliou\u00a0VS et\u00a0al (2025) Vaccination as a new form of cardiovascular prevention: a European Society of Cardiology clinical consensus statement. Eur Heart J 46:3518\u20133531","journal-title":"Eur Heart J"},{"key":"1800_CR51","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1136\/annrheumdis-2019-215882","volume":"79","author":"V Furer","year":"2020","unstructured":"Furer\u00a0V, Rondaan\u00a0C, Heijstek\u00a0MW et\u00a0al (2020) 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Annals of the Rheumatic Diseases 79:39\u201352","journal-title":"Annals of the Rheumatic Diseases"},{"key":"1800_CR52","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1001\/jama.282.15.1458","volume":"282","author":"MD Cabana","year":"1999","unstructured":"Cabana\u00a0MD, Rand\u00a0CS, Powe\u00a0NR et\u00a0al (1999) Why don\u2019t physicians follow clinical practice guidelines? A framework for improvement. JAMA 282:1458\u20131465","journal-title":"JAMA"},{"key":"1800_CR53","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s00393-024-01539-2","volume":"83","author":"J Braun","year":"2024","unstructured":"Braun\u00a0J, Albrecht\u00a0K, Callhoff\u00a0J et\u00a0al (2024) Rheumatological care in Germany : Memorandum of the German Society for Rheumatology and Clinical Immunology 2024. Z Rheumatol 83:249\u2013284","journal-title":"Z Rheumatol"},{"key":"1800_CR54","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m3216","volume":"370","author":"JL Kwan","year":"2020","unstructured":"Kwan\u00a0JL, Lo\u00a0L, Ferguson\u00a0J et\u00a0al (2020) Computerised clinical decision support systems and absolute improvements in care: meta-analysis of controlled clinical trials. BMJ 370:m3216","journal-title":"BMJ"},{"key":"1800_CR55","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-024-03588-5","volume":"22","author":"L Heath","year":"2024","unstructured":"Heath\u00a0L, Stevens\u00a0R, Nicholson\u00a0BD et\u00a0al (2024) Strategies to improve the implementation of preventive care in primary care: a systematic review and meta-analysis. BMC Med 22:412","journal-title":"BMC Med"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-026-01800-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00393-026-01800-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-026-01800-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T13:03:01Z","timestamp":1777381381000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00393-026-01800-w"}},"subtitle":["Evidenzbasierte Strategien zur Risikoreduktion in der rheumatologischen Praxis","Evidence-based strategies for risk reduction in rheumatologic practice"],"short-title":[],"issued":{"date-parts":[[2026,4,8]]},"references-count":55,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["1800"],"URL":"https:\/\/doi.org\/10.1007\/s00393-026-01800-w","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,8]]},"assertion":[{"value":"9 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autoren und Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"S.\u00a0Kleinert\n                      : A.\u00a0Finanzielle Interessen: Forschungsf\u00f6rderung der Firma Novartis an RheumaDatenRhePORT GbR, SK ist Mitglied und Gesch\u00e4ftsf\u00fchrer der GbR. \u2013\u00a0Honorare: f\u00fcr Phase\u00a03-Studien: Novartis; Honorare f\u00fcr Adboards, Vortr\u00e4ge, \u00e4hnliches: Abbvie, Novartis, Alfasigma, Galapagos, Chugai.\u00a0\u2013 nur Adboards, siehe\u00a0II. \u2013\u00a0Mitglied und Gesch\u00e4ftsf\u00fchrer RheumaDatenRhePORT GbR, Erlangen (Rhadar.de).\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Niedergelassene:r Internist:in, Rheumatologe: Erlangen (PGRN.de) | Mitgliedschaften: DGRh, BDRh, ACR.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Autoren"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf\n                      \n                      .","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Wissenschaftliche Leitung"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}}]}}